GE HealthCare (Nasdaq:GEHC) today reported second-quarter financial results that topped the consensus Wall Street forecast.
Shares of GEHC were up more than 11% to $71.44 apiece by afternoon trading today.
The Chicago-based imaging technology giant reported profits of $561 million. That equals $1.24 per share on sales of $5.295 billion for the three months ended June 30, 2026.
GE HealthCare recorded a 15.4% bottom-line gain on a sales increase of 5.8%.
Adjusted to exclude one-time items, earnings per share came in at $1.13. That landed 9¢ ahead of expectations on Wall Street. Sales also topped forecasts as experts projected $5.26 billion in revenue.
GE HealthCare said its Pharmaceutical Diagnostics (15.6% growth year-over-year) and Advanced Imaging Solutions (7.9% growth) drove revenue increases. Patient Care Solutions “continued to be challenged,” with sales dropping 13.3% compared to the same period last year. Highlights for the quarter included integration with Medtronic’s Stealth AXiS robotic technology and an expanded collaboration with RadNet. GE HealthCare also won FDA clearance for AI-enabled radiotherapy technology and added new upgrade pathways for its Allia image-guided solutions (IGS) platform.
The company said current period measures of net income benefited from International Emergency Economic Powers Act (IEEPA) tariff refunds recognized of $129 million for net income. The company said its margins saw a negative impact from a decline in Patient Care Solutions and inflation related to memory chips, oil and freight costs.
GE HealthCare reaffirmed its guidance for 2026. It continues to expect adjusted EPS to range between $4.80 and $5.00 for the full year. The company projects organic sales growth between 3% and 4%.
GE HealthCare President and CEO Peter Arduini said:
“We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products. In Patient Care Solutions, while we are focused on returning the business to growth and profitability, we are reviewing strategic options to maximize its long-term value. Our continued investment in precision innovation is expanding our addressable markets, strengthening our competitive position and supporting durable short- and long-term growth.”
